Clinical Efficacy of Modified Xiaofengsan and Its Effect on Cytokines in Persistent Asthma Patients with Wind-asthma Pattern
10.13422/j.cnki.syfjx.20190119
- VernacularTitle: 加味消风散治疗支气管哮喘风哮证的疗效观察及对炎症因子的影响
- Author:
Lin JIA
1
;
Lei WU
1
;
Bo-lin LI
1
;
Li-ying WEI
1
Author Information
1. Hebei Province Hospital of Traditional Chinese Medicine, Shijiazhuang 050031, China
- Publication Type:Research Article
- Keywords:
bronchial asthma;
wind-asthma pattern;
interleukin-4(IL-4);
interleukin-6(IL-6);
interleukin-13(IL-13)
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(4):70-74
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the clinical efficacy of modified Xiaofengsan and its effect on cytokines in persistent asthma patients with wind-asthma pattern. Method: The 120 eligible patients with chronic and persistent asthma were randomly divided into control group (60 cases) and treatment group (60 cases). Patients in control group received the budesonide/formoterol (160 μg/4.5 μg, 2 inhales/time, bid). Patients in treatment group additionally received the modified Xiaofengsan combined with budesonide/formoterol (160 μg/4.5 μg). The treatment course was 1 month in both groups. The clinical efficacy of the two groups was observed. Before and 3 months after treatment, asthma control test (ACT) and the average times of acute exacerbation in 6 months before and after treatment between two groups were observed; percentage of forced expiratory volume in first second and its predicted value (FEV1%), variety ratio of Peak expiratory flow (PEF), eosinophilic granulocyte (EOS) count in peripheral blood and the levels of interleukin-4(IL-4), interleukin-6(IL-6) and interleukin-13(IL-13) in serum were measured before and after treatment respectively. In addition, the safety of the two groups was evaluated. Result: The total effective rate of the treatment group was higher than that of the control group (P<0.05). The levels of ACT value and FEV1% in treatment group were higher(P<0.05), while the average times of acute exacerbation, PEF variety ratio, EOS count in peripheral blood, L-4, IL-6 and IL-13 in serum were lower(P<0.05) than those in control group after treatment. There was no significant difference in incidence of the adverse reactions. Conclusion: Modified Xiaofengsan combined with budesonide/formoterol could relieve symptoms of asthma, improve pulmonary function and lower the levels of IL-4, IL-6 and IL-13 in serum.
